Seattle-based biotech Kineta has raised nearly $800,000. The company, which focuses on accelerating drug research, said the investment will go toward general drug development and "pipeline advancement," specifically for clinical trials like its recently announced phase 1 trial for ShK-186, which treats psoriasis. The company is also doing research to stop the spread of Ebola and other viruses. The psoriasis trial will evaluate the effects of bi-weekly injections of the drug for four weeks in patients…
Kineta's Plans: Research For Ebola, New Funding For Psoriasis Clinical Trials
Annie Zak, Biz Journals
Tue, 10/21/2014 - 1:49pm
BING NEWS:
- Home Phototherapy for Psoriasis: Encouraging New Data, Optimizing Access
The ideal candidate "is averse to using systemic agents but whose disease is beyond the point where topical medicines alone will work," Craig A. Elmets, MD, said.
05/21/2024 - 9:57 pm | View Link - Study uncovers key biological pathways driving psoriasis inflammation
A certain biological pathway, a set of linked reactions in the body, drives the inflammation seen in the skin disease psoriasis, a new study finds.
05/20/2024 - 4:21 pm | View Link - More
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more